AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript

Jim Clemmer: Yeah. Great call. And we’ll give you guys more kind of a commercial plan look over the coming quarters and months. But we’re going to say, we think there’s a lot of care that’s going to be delivered in OBLs. We already know other centers outside the hospital over time and being thrombectomy maybe one of those things that gets care delivery more in OBL like setting. Today, it’s not driving this though, Matt. It’s really because this technology is so special in Auryon. We believe so deeply in the science and how it performs. So we’re going to make the commercial shifts necessary to make sure we can also accommodate the use of it to be really successful for small vessel DVT treatment, the bulk of which we believe will occur in a hospital setting at this point.

Matthew Mishan: And then just a last question. Maybe I missed it over like the last quarter or two. Just what happened to – what’s happening with pancreas with NanoKnife? Is there any update on where enrollment is in those DIRECT trials?

Steve Trowbridge: So we haven’t given any specific updates on where the enrollment is. It’s moving forward. It’s continuing to go. As we’ve talked about, that was a trial that had the two arms, the registry side as well as the RCT. The RCT is going to be very difficult. That’s proven to be true in terms of the enrollment there. The other thing that we said is that given the structure of the PRESERVE trial, we expected that PRESERVE would outpace DIRECT even though it started later. We’re seeing that as well, that enrollment is really outpacing it. So we’re still focused on DIRECT. We’re still pretty happy with what we’re seeing given all of the contextual things that are going on in today’s environment and moving forward. And then as we continue to get more – hit milestones and things like that, we’ll let you know.

Matthew Mishan: All right. Thank you very much.

Jim Clemmer: Thanks, Matt.

Steve Trowbridge: Thanks.

Operator: Thank you. I’d now like to turn the call back over to Mr. Clemmer for any closing remarks. Mr. Clemmer?

Jim Clemmer: Thanks, Rob and investors. Thanks for joining us today. And as I said earlier, we’re a company committed to our platform technologies and to ensuring that we can be a care delivery partner with our customers and the physicians that trust us. Thanks again to our AngioDynamics team for working in a really challenging environment and delivering for our customers. Have a great day.

Operator: This will conclude today’s conference. You may disconnect your lines at this time. We thank you for your participation.